AstraZeneca shares drop after $400bn Bristol-Myers deal talks
A potential $400bn merger between AstraZeneca and Bristol-Myers Squibb would create the world's fourth-largest drugmaker but faces investor skepticism.
En bref
AstraZeneca shares fell nearly 9% after reports it was in talks to acquire Bristol-Myers Squibb for $400bn. The combined company would rank among the world's largest pharmaceutical firms.
AstraZeneca shares dropped 8.9% after reports of merger talks with Bristol-Myers Squibb.7 A potential $400bn deal would create one of the world's largest pharmaceutical groups.7,6,5,4,3,2 The combined company would be the world's fourth-largest drugmaker by market value.7,5
More than £17bn was wiped off AstraZeneca's market value following the reports.7 AstraZeneca and Bristol-Myers Squibb have held early-stage discussions about combining.2 The companies have discussed a potential merger over several months, according to reports.4,3
Bloomberg Intelligence's Sam Fazeli stated a takeover would make no sense.8,5 Investors questioned the rationale for the deal, with some calling it illogical.8,7 Bristol-Myers Squibb shares surged on news of the potential acquisition.6
AstraZeneca's shares fell while Bristol-Myers Squibb's shares rose in trading.6 The reported deal value was initially described as $400bn in multiple outlets.7,6,5,4,3,2 One report cited a potential deal value of $512bn, differing from other estimates.1
The merger talks remain at an early stage and may not result in a deal.2 AstraZeneca is the UK's largest drugmaker by market value.7 AstraZeneca is run from the UK but operates globally.7
Où les médias divergent
Pourquoi c’est important
AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, UK.7
Bristol-Myers Squibb is a major US-based pharmaceutical company known for cancer treatments and immunology drugs.7,6
The pharmaceutical industry has seen a wave of large mergers in recent years as companies seek to expand pipelines and market reach.7,4
- Plus sur
- Stocks
Ce texte a été rédigé à partir des 8 articles listés ci-dessous, publiés par 5 médias indépendants, et vérifié ligne par ligne. Ce n’est la copie d’aucun d’eux. Une erreur ? Dites-le nous.
Discussion
0Comments are screened automatically. Disagreement is fine; abuse and spam are not.
Loading…
Related
UK approves $110B Paramount-Warner Bros merger
UK regulators approve the Paramount-Skydance takeover of Warner Bros. Discovery, but the deal still faces a U.S. antitrust trial in California.
SK Hynix shares rise on buyback speculation
SK Hynix shares advanced after overnight gains in US chipmakers and reports of a potential shareholder return plan.
Paramount CEO Ellison defends politics as antitrust trial set for March 2027
Ellison said trust in his handling of CNN is being questioned, while a judge set the merger's antitrust trial for March 2027 and the company lifted its profit outlook.
News Øresund - Johan Wessman / CC BY 3.0Novo Nordisk shares fall as Wegovy pill sales miss forecasts
Novo Nordisk raised its full-year guidance for obesity and diabetes drugs but its US shares declined after the Wegovy weight-loss pill's sales did not meet analyst expectations.